Pruritus
PRA-523 is a highly potent, selective 5-HT7 antagonist that displays peripherally restricted pharmacokinetic, good dermal penetration/permeability, and safe preliminary ADMET profiles. [more about MOA]
Our approach to blocking 5-HT7 with a selective 5-HT7 antagonist is a first-in-class approach to treat pruritus. Through the completion of further research and development activities for PRA-523, Praeventix is committed and well-positioned to disrupt and displace existing therapies, achieving our goal of bringing new treatment options to and improving the quality of life of patients suffering from serotonergic driven disorders, including pruritus.
PRA-523
PRA-523 is a highly potent, selective 5-HT7 antagonist that displays peripherally restricted pharmacokinetic, good dermal penetration/permeability, and safe preliminary ADMET profiles. [more about MOA]
Our approach to blocking 5-HT7 with a selective 5-HT7 antagonist is a first-in-class approach to treat pruritus. Through the completion of further research and development activities for PRA-523, Praeventix is committed and well-positioned to disrupt and displace existing therapies, achieving our goal of bringing new treatment options to and improving the quality of life of patients suffering from serotonergic driven disorders, including pruritus.